Loading
Moleculin Biotech, Inc. Stock: price and insider trades · United States
3 insiders bought shares over the last 90 days, the latest filed 05 Aug 2026.
Moleculin Biotech, Inc.: what insiders have been doing
Moleculin Biotech, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). The last twelve months, up to 18 October 2026, brought 18 filings signed by 3 insiders.
Not one open-market sale was filed. On the buying side, 3 insiders reported 3 purchases. The amount is not disclosed for 3 filings. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. On the buying side, the filings list 1 finance chief, 1 senior executive and 1 chief executive among the declarants.
Compared with its exchange (5,816 companies, median 19 filings), a count of 18 filings is below the norm. Our records for Moleculin Biotech, Inc. go back to 2021, with 9 purchases and no sales on the open market in total.
The clock since the last published purchase (5 August 2026) now reads 73 days. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
53
Thresholds
n/a
Buy Volume
€305,356
9 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleDonald H. Picker1 buy
Jonathan P. Foster1 buy
Walter Klemp V1 buy
Since the insiders bought
- -85.3%Entry US$281.25 · Close at T+365 US$41.25
- -85.3%Entry US$281.25 · Close at T+365 US$41.25
- -85.3%Entry US$281.25 · Close at T+365 US$41.25
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.41
Analyst consensus
3 analysts1.33/5
US$2.00Target US$12.00(+2820%)US$31.00
Income statement
EBITDA-US$25M
Net income-US$33.7M0.0% margin
Valuation
PER (trailing)0.0x
PER (forward)-0.0x
P/Book0.3x
Beta2.00
Balance sheet & cash
Market capUS$8.4M
Total debtUS$359k
Free Cash Flow-US$22.7M
Debt / Equity3%
Profitability & ownership
ROE-1371.6%
ROA-84.6%
% insiders6.1%
% institutions8.2%
Last declaration on 16 October 2026
Declarations53 total
207,500 sharesCommon StockSEC:0001437749-26-032865:0
48,659 shares@ US$0.3701Common StockSEC:0001437749-26-032865:1
130,000 sharesCommon StockSEC:0001437749-26-032864:0
30,485 shares@ US$0.3701Common StockSEC:0001437749-26-032864:1
293,333 sharesCommon StockSEC:0001437749-26-025929:0
Canonical exit: 1 Nov 2026 (T+90)
533,333 sharesCommon StockSEC:0001437749-26-025928:0
Canonical exit: 1 Nov 2026 (T+90)
173,333 sharesCommon StockSEC:0001437749-26-025927:0
Canonical exit: 1 Nov 2026 (T+90)
109 sharesCommon StockSEC:0001437749-26-021610:0
31 sharesCommon StockSEC:0001437749-26-021610:1
174 sharesCommon StockSEC:0001437749-26-021610:2
41 sharesCommon StockSEC:0001437749-26-021610:3
150 sharesCommon StockSEC:0001437749-26-021611:0
37 sharesCommon StockSEC:0001437749-26-021611:1
360 sharesCommon StockSEC:0001437749-26-021611:2
88 sharesCommon StockSEC:0001437749-26-021611:3
8,750 sharesCommon StockSEC:0001437749-25-033684:0
28,750 sharesCommon StockSEC:0001437749-25-033683:0
20,625 sharesCommon StockSEC:0001437749-25-033682:0
2,711 sharesCommon StockSEC:0001437749-25-021051:0
3,750 sharesCommon StockSEC:0001437749-25-021050:0
1,078 sharesCommon StockSEC:0001437749-25-021049:0
833 sharesCommon StockSEC:0001437749-25-020803:0
1,667 sharesCommon StockSEC:0001437749-25-020802:0
982 sharesCommon StockSEC:0001437749-24-022252:0
1,766 sharesCommon StockSEC:0001437749-24-021199:0
25 of 53 declarations
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a U.S.-based biopharmaceutical company listed on the Nasdaq market in the United States and focused on the clinical development of therapies for hard-to-treat cancers and, to a more limited extent, viral diseases. Headquartered in Houston, Texas, the company was formed in July 2015 and has since remained a research-driven biotech with a portfolio built around proprietary drug candidates rather than marketed products. As a result, Moleculin should be viewed as a clinical-stage company whose valuation is highly dependent on trial outcomes, regulatory progress, and access to external capital.
The company’s lead asset is Annamycin, a next-generation anthracycline designed to address multidrug resistance mechanisms and avoid the cardiotoxicity associated with many traditional anthracyclines. Moleculin is developing Annamycin primarily for relapsed or refractory acute myeloid leukemia (R/R AML) and for soft tissue sarcoma lung metastases. The lead AML program is MIRACLE, a pivotal adaptive Phase 2B/3 study evaluating Annamycin in combination with cytarabine. Moleculin also develops WP1066, an immune/transcription modulator that targets STAT3 and related oncogenic pathways, with ongoing or planned research in brain tumors, pancreatic cancer, and other oncology settings. A third program, WP1122, is being explored for potential antiviral applications and selected oncology indications.
Read moreShow less
From a competitive standpoint, Moleculin operates in a highly contested small-cap biotech segment dominated by better-capitalized peers with broader pipelines and stronger funding flexibility. Its differentiators are scientific specificity, a focus on high-unmet-need cancer indications, and the possibility of significant upside if one of its lead programs succeeds clinically or advances toward approval. The trade-off is substantial execution risk and ongoing financing dependence; the company has repeatedly indicated that additional capital will be required to support its clinical development plans.
Recent developments have been clinically meaningful. In 2025 and early 2026, Moleculin reported continued progress in the MIRACLE trial, including completion of treatment for the 45 patients required for the first planned interim unblinding and geographic expansion of enrollment across multiple countries. The company also released positive topline data for Annamycin in soft tissue sarcoma lung metastases and positive Phase 1 results for WP1066 in pediatric recurrent malignant brain tumors. For French, Belgian, and Swiss investors, Moleculin remains a speculative Nasdaq-listed healthcare name in the United States: potentially high reward, but with elevated clinical, regulatory, and financing risk.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
